On December 11, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the anti-CD19 single-chain antibody chimeric antigen receptor T cell injection (referred to as CAR-T-19 cell injection) developed by Boai NKY Medical's affiliated company IMMUNOTECH-B (06978.HK) has successfully been included in the list of breakthrough therapies by CDE, with the indication for relapsed/refractory B-cell acute lymphoblastic leukemia in patients aged 25 years and younger.
新开源参股公司永泰生物产品获CDE突破性疗法认定
Boai NKY Medical's affiliated company IMMUNOTECH-B has obtained breakthrough therapy designation from CDE for its products.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated